JP2015516155A - 乳がん予後判定、プロゲステロン受容体サブタイプの予測および遺伝子発現に基づく抗プロゲスチン処置に対する応答の予測 - Google Patents

乳がん予後判定、プロゲステロン受容体サブタイプの予測および遺伝子発現に基づく抗プロゲスチン処置に対する応答の予測 Download PDF

Info

Publication number
JP2015516155A
JP2015516155A JP2015508975A JP2015508975A JP2015516155A JP 2015516155 A JP2015516155 A JP 2015516155A JP 2015508975 A JP2015508975 A JP 2015508975A JP 2015508975 A JP2015508975 A JP 2015508975A JP 2015516155 A JP2015516155 A JP 2015516155A
Authority
JP
Japan
Prior art keywords
expression
gene
cancer
genes
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015508975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516155A5 (https=
Inventor
キャロル アン レンジ
キャロル アン レンジ
トッド フィリップ クヌツソン
トッド フィリップ クヌツソン
ジェイソン バシル ニカス
ジェイソン バシル ニカス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2015516155A publication Critical patent/JP2015516155A/ja
Publication of JP2015516155A5 publication Critical patent/JP2015516155A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015508975A 2012-04-27 2013-03-15 乳がん予後判定、プロゲステロン受容体サブタイプの予測および遺伝子発現に基づく抗プロゲスチン処置に対する応答の予測 Pending JP2015516155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639407P 2012-04-27 2012-04-27
US61/639,407 2012-04-27
PCT/US2013/032677 WO2013162776A1 (en) 2012-04-27 2013-03-15 Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression

Publications (2)

Publication Number Publication Date
JP2015516155A true JP2015516155A (ja) 2015-06-11
JP2015516155A5 JP2015516155A5 (https=) 2016-05-12

Family

ID=48045769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015508975A Pending JP2015516155A (ja) 2012-04-27 2013-03-15 乳がん予後判定、プロゲステロン受容体サブタイプの予測および遺伝子発現に基づく抗プロゲスチン処置に対する応答の予測

Country Status (14)

Country Link
US (1) US10501800B2 (https=)
EP (1) EP2841594A1 (https=)
JP (1) JP2015516155A (https=)
KR (1) KR20150028232A (https=)
AU (1) AU2013252913A1 (https=)
CA (1) CA2871590A1 (https=)
HK (1) HK1208057A1 (https=)
IL (1) IL235351A0 (https=)
MX (1) MX2014013044A (https=)
NZ (1) NZ701652A (https=)
PH (1) PH12014502410A1 (https=)
RU (1) RU2014147625A (https=)
WO (1) WO2013162776A1 (https=)
ZA (1) ZA201407853B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501800B2 (en) 2012-04-27 2019-12-10 Regents Of The University Of Minnesota Breast cancer prognosis
WO2022075113A1 (ja) * 2020-10-08 2022-04-14 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
JP2024160217A (ja) * 2020-03-17 2024-11-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療に対するレスポンダを決定するための方法およびシステム

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140363425A1 (en) * 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US20150276767A1 (en) * 2014-03-12 2015-10-01 The University Of Sydney Systems and methods for identifying cancers having activated progesterone receptors
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US10942183B2 (en) 2017-04-05 2021-03-09 Regents Of The University Of Minnesota Methods of detecting progesterone receptor and of detecting an expression level
EP3822368A1 (en) 2019-11-14 2021-05-19 Koninklijke Philips N.V. Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression
US20250005743A1 (en) * 2023-06-30 2025-01-02 Mackay Memorial Hospital Method and system for identifying hormone receptor status

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000618A2 (en) * 2000-06-28 2002-01-03 University Technology Corporation Progesterone receptor-regulated gene expression and methods related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
MX2014013044A (es) 2012-04-27 2015-06-23 Univ Minnesota Pronostico de cancer de mamas, prediccion de subtipo de receptor de progesterona y prediccion de respuesta a tratamiento de antiprogestina basado en la expresion de genes.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000618A2 (en) * 2000-06-28 2002-01-03 University Technology Corporation Progesterone receptor-regulated gene expression and methods related thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6017004480; ＢＭＣ Ｍｏｌ． Ｂｉｏｌ．， ２０１２．０３．２２， Ｖｏｌ．１３， １０ *
JPN6017004481; Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ．， ２００９， Ｖｏ．１０６， Ｎｏ．３４， ｐ．１４２８７-１４２９２ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501800B2 (en) 2012-04-27 2019-12-10 Regents Of The University Of Minnesota Breast cancer prognosis
JP2024160217A (ja) * 2020-03-17 2024-11-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療に対するレスポンダを決定するための方法およびシステム
WO2022075113A1 (ja) * 2020-10-08 2022-04-14 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
JP2022062465A (ja) * 2020-10-08 2022-04-20 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
JP7619556B2 (ja) 2020-10-08 2025-01-22 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー

Also Published As

Publication number Publication date
AU2013252913A1 (en) 2014-11-27
WO2013162776A1 (en) 2013-10-31
US20130316992A1 (en) 2013-11-28
IL235351A0 (en) 2014-12-31
EP2841594A1 (en) 2015-03-04
ZA201407853B (en) 2015-12-23
US10501800B2 (en) 2019-12-10
KR20150028232A (ko) 2015-03-13
RU2014147625A (ru) 2016-06-20
CA2871590A1 (en) 2013-10-31
HK1208057A1 (en) 2016-02-19
PH12014502410A1 (en) 2015-01-12
MX2014013044A (es) 2015-06-23
NZ701652A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
US10501800B2 (en) Breast cancer prognosis
US12280066B2 (en) Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
Knutson et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression
Modugno et al. Hormone response in ovarian cancer: time to reconsider as a clinical target?
Yang et al. Progesterone: the ultimate endometrial tumor suppressor
US8877445B2 (en) Methods for identification of tumor phenotype and treatment
JP6550045B2 (ja) 乳がんに由来する骨の転移がんの予後診断および処置のための方法
Ghayad et al. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer
Irish et al. Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer
Willis et al. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs
US20240355476A1 (en) Methods and compositions related to triple-negative breast cancer
Huang et al. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors
Mandato et al. HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study
Okada et al. Changes in ontogenetic expression of estrogen receptor alpha and not of estrogen receptor beta in the female rat reproductive tract
Zamagni et al. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies
Helland Tamoxifen in the treatment of luminal breast cancer
Waissengrin et al. The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer
US10942183B2 (en) Methods of detecting progesterone receptor and of detecting an expression level
Gilfillan et al. Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1
Nyante Single nucleotide polymorphisms and the etiology of basal-like and luminal A breast cancer: a pathway-based approach
Campion Progesterone Receptor Isoform Signaling In Ovarian Cancer Cellular Senescence
Shou-Tung et al. Analysis of genetic alterations in plasma DNA from breast cancer patients: a possible molecular biomarker in early detection and prognosis of breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170913